Research progress of colchicine in the treatment of heart failure with preserved ejection fraction

Heart failure with preserved ejection fraction(HFpEF) is a heart failure syndrome with high morbidity and mortality, and its pathogenesis has not been fully elucidated. Chronic low-grade systemic inflammation is considered to be the basic pathological mechanism of HFpEF, which promotes the development of cardiomyocyte stiffnessand myocardial fibrosis. However, anti-inflammatory treatment of HFpEF patients has not received enough attention and research. Colchicine is a classic anti-inflammatory drug that inhibits inflammasome activation and the release of cytokines, including IL-1β and hs-CRP. The benefits of colchicine in patients with coronary artery disease have been well established, and the results of COLCOT and LoDoCo2 studiesshowed that colchicine significantly reduced the level of inflammation and the risk of long-term cardiovascular events in patients with coronary heart disease. However, the research on colchicine in the treatment of HFpEF is very limited and has not received much attention. This article summarizes the existing clinical and preclinical research evidence, aiming to review and prospect the application prospect of colchicine in the treatment of HFpEF.